부산대학교 도서관

Objectives: This study analyzes the relationship between biglycan expression in prostate cancer and clinicopathological parameters to clarify the potential link between biglycan and prognosis and progression to castration‐resistant prostate cancer (CRPC). Methods: We retrospectively analyzed 60 cases of prostate cancer patients who underwent robot‐assisted laparoscopic radical prostatectomy in Hokkaido University Hospital. Results: Biglycan was expressed in the tumor stroma but not in tumor cells. There was no significant relationship with biochemical recurrence (p = 0.5237), but the expression of biglycan was 36.1% in the group with progression to CRPC. This indicates a significant relationship with progression to CRPC (p = 0.0182). Furthermore, the expression of biglycan‐positive blood vessels was significantly higher (15.9%) in the group with biochemical recurrence than in the group without biochemical recurrence (8.5%) (p = 0.0169). The biglycan‐positive vessels were 28.6% in the group with progression to CRPC, which was significantly higher than that in the group without progression to CRPC (p < 0.0001). Conclusion: This is the first study to show that stroma biglycan is a useful prognostic factor for prostate cancer. [ABSTRACT FROM AUTHOR]